Published in Clin Exp Immunol on June 01, 1990
Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol (1991) 1.19
Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells. Immunology (1992) 1.14
Eosinophils and disease pathogenesis. Semin Hematol (2012) 1.05
Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest (1997) 0.96
Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes. J Immunol (2008) 0.95
Priming of eosinophils by GM-CSF is mediated by protein kinase CbetaII-phosphorylated L-plastin. J Immunol (2011) 0.93
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. J Blood Med (2013) 0.89
Alternaria fungus induces the production of GM-CSF, interleukin-6 and interleukin-8 and calcium signaling in human airway epithelium through protease-activated receptor 2. Int Arch Allergy Immunol (2012) 0.88
Patients with allergic rhinitis and allergic asthma share the same pattern of eosinophil and neutrophil degranulation after allergen challenge. Clin Mol Allergy (2011) 0.87
Inhibition of IL-32 signaling by bamboo salt decreases pro-inflammatory responses in cellular models of allergic rhinitis. J Med Food (2014) 0.76
Interleukin-3 production by mast cells from human lung. Inflammation (1999) 0.75
Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature (1984) 4.46
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest (1986) 3.78
Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J (1988) 2.83
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Studies on blood eosinophils. I. Patients with a transient eosinophilia. Clin Exp Immunol (1976) 2.22
Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol (1983) 2.17
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci U S A (1987) 1.89
Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest (1986) 1.76
Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature (1984) 1.75
Activated human eosinophils generate SRS-A leukotrienes following IgG-dependent stimulation. Nature (1985) 1.51
Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem (1989) 1.49
Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density. Clin Exp Immunol (1984) 1.28
Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J Immunol (1987) 1.23
Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest (1979) 1.20
The mechanisms which produce vacuolated and degranulated eosinophils. Br J Haematol (1981) 1.19
Role of specific IgE antibodies in peroxidase (EPO) release from human eosinophils. J Immunol (1986) 1.11
Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood (1987) 1.10
Granulocyte-macrophage colony-stimulating factor modulates the excitation-response coupling sequence in human neutrophils. J Immunol (1988) 1.03
Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol (1987) 1.02
Recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) regulates f Met-Leu-Phe receptors on human neutrophils. Immunology (1988) 1.02
Nedocromil sodium and cromolyn (sodium cromoglycate) selectively inhibit antibody-dependent granulocyte-mediated cytotoxicity. Int Arch Allergy Appl Immunol (1988) 0.97
Plasma membrane antigens on light density and activated human blood eosinophils. Clin Exp Immunol (1985) 0.96
Monoclonal antibodies to human eosinophil plasma membrane antigens enhance the secretion of eosinophil cationic protein. Clin Exp Immunol (1986) 0.90
Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J Immunol (1989) 0.88
Evidence for secretion of human eosinophil granule major basic protein and Charcot-Leyden crystal protein during eosinophil maturation. Exp Hematol (1984) 0.87
The effects of complement activation by cobra venom factor on the migration of T and B lymphocytes into rat thoracic duct lymph. Immunology (1977) 0.85
Partial purification and biological properties of an eosinophil-activating factor. Eur J Immunol (1985) 0.85
Studies on C3ahu binding to human eosinophils: characterization of binding. Int Arch Allergy Appl Immunol (1984) 0.84
Eosinophil-activating factor (EAF) production by a human cell line (ESH 98) stimulated with tumour necrosis factor. Immunology (1988) 0.78
Studies on blood eosinophils. I. Patients with a transient eosinophilia. Clin Exp Immunol (1976) 2.22
Studies on blood eosinophils. II. Patients with Löffler's cardiomyopathy. Clin Exp Immunol (1976) 2.10
Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet (1987) 1.98
Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med (1983) 1.96
Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature (1984) 1.75
Large mononuclear (veiled) cells like 'Ia-like' membrane antigens in human afferent lympn. Clin Exp Immunol (1980) 1.74
Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis (1985) 1.63
Cardiovascular features of 11 patients with eosinophilic endomyocardial disease. Q J Med (1983) 1.62
Activated eosinophils in familial eosinophilic gastroenteritis. Gastroenterology (1985) 1.59
Activated human eosinophils generate SRS-A leukotrienes following IgG-dependent stimulation. Nature (1985) 1.51
Toxic effects of human eosinophil products on isolated rat heart cells in vitro. Biochem J (1982) 1.46
The hypereosinophilic syndrome: clinical features, laboratory findings and treatment. Allergy (1982) 1.43
Mechanism of eosinophilia. V. Kinetics of normal and accelerated eosinopoiesis. Cell Tissue Kinet (1971) 1.42
Echocardiographic features of eosinophilic endomyocardial disease. Br Heart J (1982) 1.24
A comparison of the clinical and cardiological features of endomyocardial disease in temperate and tropical regions. Postgrad Med J (1983) 1.23
The mechanisms which produce vacuolated and degranulated eosinophils. Br J Haematol (1981) 1.19
Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol (1991) 1.19
A vascular endothelial cell antigen with restricted distribution in human foetal, adult and malignant tissues. Immunology (1983) 1.16
Inhibition of lymphocyte recirculation by stress and corticotropin. Cell Immunol (1972) 1.14
Mechanism of eosinophilia. VI. Eosinophil mobilization. Cell Tissue Kinet (1971) 1.13
Successful surgical treatment of two patients with eosinophilic endomyocardial disease. Br Heart J (1981) 1.12
Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils. J Clin Invest (1991) 1.10
The cardiotoxicity of eosinophils. Postgrad Med J (1983) 1.09
Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br Med J (Clin Res Ed) (1984) 1.06
Echocardiographic features of tropical endomyocardial disease in South India. Br Heart J (1983) 1.04
Enzymes altering the binding capacity of human blood eosinophils for IgG antibody-coated erythrocytes (EA). Clin Exp Immunol (1980) 1.04
Killing of Plasmodium falciparum by eosinophil secretory products. Infect Immun (1987) 1.01
Mechanism of eosinophilia. IV. The pulmonary lesion resulting from intravenous injection of Trichinella spiralis. Yale J Biol Med (1971) 1.00
Active participation of eosinophils in patch test reactions to inhalant allergens in patients with atopic dermatitis. Br J Dermatol (1988) 0.98
Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology (1982) 0.98
The detection of endothelial cell antigens in cutaneous tissue using methacarn and periodate lysine paraformaldehyde fixation. J Immunol Methods (1986) 0.97
The pathogenesis of eosinophilic endomyocardial disease in patients with carcinomas of the lung. Heart Vessels (1985) 0.97
Eosinophilic disorders affecting the myocardium and endocardium: a review. Heart Vessels Suppl (1985) 0.96
Plasma membrane antigens on light density and activated human blood eosinophils. Clin Exp Immunol (1985) 0.96
Inappropriate secretion of antidiuretic hormone with chronic chest infections. Br Med J (1974) 0.94
Eosinophils as effector cells in disease. Schweiz Med Wochenschr (1978) 0.94
Purification of normal human eosinophils using the different binding capacities of blood leucocytes for complexed rabbit IgG. Clin Exp Immunol (1977) 0.92
Pleural mesothelioma and hypoglycaemia. Proc R Soc Med (1968) 0.91
Monoclonal antibodies to human eosinophil plasma membrane antigens enhance the secretion of eosinophil cationic protein. Clin Exp Immunol (1986) 0.90
Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome. Immunology (1994) 0.90
Eosinophilia and allergic reactions to drugs. Clin Haematol (1980) 0.90
Human immunodeficiency virus infection of eosinophils in human bone marrow cultures. J Exp Med (1991) 0.89
Hypereosinophilic syndrome preceding T cell lymphoblastic lymphoma. Clin Lab Haematol (1985) 0.88
Tropical eosinophilia. Semin Hematol (1982) 0.88
Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J Immunol (1989) 0.88
Synergism between eosinophil cationic protein and oxygen metabolites in killing of schistosomula of Schistosoma mansoni. J Immunol (1987) 0.88
Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome. Br J Dermatol (1990) 0.88
Increased eosinophil colony formation in agar by haemopoietic cells from patients with the hypereosinophilic syndrome. Clin Lab Haematol (1981) 0.87
Lymphomatoid papulosis and its relationship to "idiopathic" hypereosinophilic syndrome. J Am Acad Dermatol (1988) 0.87
Tissue localization of human eosinophil cationic proteins in allergic diseases. Int Arch Allergy Appl Immunol (1985) 0.85
Partial purification and biological properties of an eosinophil-activating factor. Eur J Immunol (1985) 0.85
The effects of complement activation by cobra venom factor on the migration of T and B lymphocytes into rat thoracic duct lymph. Immunology (1977) 0.85
Expression of lacto-N-fucopentaose III (CD15)- and sialyl-Lewis X-bearing molecules and their functional properties in eosinophils from patients with the idiopathic hypereosinophilic syndrome. Immunology (1994) 0.84
Strongyloides stercoralis infection and small intestinal lymphoma. Parasite Immunol (1979) 0.84
Reversible granulocyte killing defect in anorexia nervosa. Clin Exp Immunol (1975) 0.83
Alterations in blood eosinophil morphology, binding capacity for complexed IgG and kinetics in patients with tropical (filarial) eosinophilia. Parasite Immunol (1981) 0.81
The origin, kinetics and distribution of large lymphocytes from the thoracic duct of rats with trichinosis. Immunology (1972) 0.81
Purification of eosinophil peroxidase and studies of biosynthesis and processing in human marrow cells. Blood (1985) 0.81
Human eosinophil major basic protein, a mediator of allergic inflammation, is expressed by alternative splicing from two promoters. Biochem J (1995) 0.80
Eosinophilia. Practitioner (1982) 0.80
Eosinophils and endomyocardial fibrosis. Contrib Microbiol Immunol (1983) 0.79
The in vivo cardiotoxic effect of eosinophilic cationic protein in an animal preparation. Jpn Circ J (1986) 0.79
Infection of inbred and nude (athymic) rats with Brugia spp. Parasite Immunol (1983) 0.78
Mechanism of eosinophilia. VII. Eosinophilia in rats with lymphoma. Br J Haematol (1972) 0.77
Arrhythmias in patients with hypereosinophilia: a comparison of patients with and without Löffler's endomyocardial disease. Postgrad Med J (1980) 0.77
Activation of the respiratory burst in eosinophil leucocytes--a transduction sequence decoupled from cytosolic Ca2+ rise. Eur J Clin Invest (1995) 0.77
Toxocara canis: interaction of human blood eosinophils with the infective larvae. Exp Parasitol (1986) 0.76
Solitary pyogenic liver abscess in patients with diabetes mellitus. Lancet (1966) 0.76
Hypereosinophilia in rats with Trichinella spiralis infections. Br J Exp Pathol (1980) 0.75
New properties and roles for eosinophils in disease: discussion paper. J R Soc Med (1985) 0.75
Eosinophils in eosinophilic endomyocardial disease. Postgrad Med J (1986) 0.75
The pathophysiology of endomyocardial fibrosis. Arq Bras Cardiol (1982) 0.75
Expression in Escherichia coli and purification of human eosinophil-derived neurotoxin with ribonuclease activity. Protein Expr Purif (1995) 0.75
The cellular components of tissue changes in filariasis: functional aspects. J Commun Dis (1986) 0.75
Support service management--a third choice from America? Hosp Health Serv Rev (1985) 0.75
What eosinophils do. Lancet (1977) 0.75
Letter: Chlorpheniramine-induced bone-marrow suppression. Lancet (1976) 0.75
Selective localization of intravenously injected 111indium-labelled eosinophils in rat tissues infected with Nippostrongylus brasiliensis. Parasite Immunol (1983) 0.75
Eosinophil membrane antigens: phenotypic frequencies in normal individuals and patients with the hypereosinophilic syndrome. Int Arch Allergy Appl Immunol (1985) 0.75
Issues facing transplantation in the United Kingdom. Transplant Proc (1997) 0.75
Increased retention of orally administered zinc and raised blood cell zinc concentrations in iron-deficient rats. Br J Nutr (1969) 0.75
Chromosome and cell culture studies in eosinophilic leukaemia. Br J Haematol (1986) 0.75
Priorities in Newcastle--characters in a northern landscape. Hosp Health Serv Rev (1983) 0.75
Tartrazine sensitivity in renal failure. Lancet (1979) 0.75
Outlook for health care--a local management view. Hosp Health Serv Rev (1984) 0.75